Edition:
United States

TherapeuticsMD Inc (TXMD.OQ)

TXMD.OQ on NASDAQ Stock Exchange Global Select Market

5.47USD
20 Aug 2018
Change (% chg)

-- (--)
Prev Close
$5.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
634,530
52-wk High
$7.66
52-wk Low
$4.34

Chart for

About

TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials... (more)

Overall

Beta: 1.46
Market Cap(Mil.): $1,258.57
Shares Outstanding(Mil.): 233.50
Dividend: --
Yield (%): --

Financials

  TXMD.OQ Industry Sector
P/E (TTM): -- 28.28 30.39
EPS (TTM): -0.44 -- --
ROI: -76.73 12.94 12.61
ROE: -109.52 14.96 14.80

TherapeuticsMD's therapy for menopause-related condition gets approval

Women's healthcare company TherapeuticsMD Inc won its first-ever U.S. approval on Wednesday with the drug regulator clearing its hormone therapy for a painful condition triggered by menopause after rejecting it a year earlier.

May 30 2018

UPDATE 2-TherapeuticsMD's therapy for menopause-related condition gets approval

* Shares volatile; last down 2 pct (Adds analyst, CEO comment, share movement)

May 30 2018

FDA approves TherapeuticsMD's hormone therapy

May 30 The U.S. Food and Drug Administration approved TherapeuticsMD Inc's hormone therapy for a painful condition triggered by menopause, the women's health company said on Wednesday.

May 30 2018

BRIEF-Therapeutics MD Reports Loss Per Share Of $0.11

* THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 03 2018

BRIEF-TherapeuticsMD Enters Into Negotiations With U.S. FDA For TX-004HR

* ENTERED INTO NEGOTIATIONS WITH U.S. FOOD AND DRUG ADMINISTRATION REGARDING PROPOSED LABEL FOR TX-004HR

Apr 11 2018

BRIEF-TherapeuticsMD Announces FDA Acceptance Of New Drug Application For Tx-001Hr

* THERAPEUTICSMD ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR TX-001HR

Mar 08 2018

Earnings vs. Estimates